I think you may be extrapolating on this situation, without fully knowing the details of product release, market expansion, and corporate demands. Releasing a product to corporate retail chains comes adjacent with a host of legal demands - most of which are not experienced when releasing a product to solely internet retailers. Every aspect of product release, from labeling nomenclature to marketing initiatives must be altered to meet the legal criterion of the aforementioned retail chains. Further, this particular compound is the definition of novel i.e., almost impossible to obtain. Rather than rush production for a preemptive release, we thought a proper release necessitates having a proper stock of said compound. If we decided to push the release, the very near future would hold massive backorders for both ourselves, and consumers, and would not please anybody; we felt a longer wait at this period is, suffice to say, less to swallow than an interrupted supply chain.
If you read my posts, I am not a hype machine, and do not contribute significantly to pre-release excitement - aside from what my comments on the pharmacology of the product may bring. I can assure you that this was not intentional, and has caused the combined efforts of the company to double. There is a reason you do not see Jacob (USPLabs) on the boards as heavily: He is tending very carefully to the supply chain. Patience is a virtue, and I promise PRIME will be worth the wait.